Post-thaw viable CD34+ cell count is a valuable predictor of haematopoietic stem cell engraftment in autologous peripheral blood stem cell transplantation

被引:53
|
作者
Lee, S. [1 ]
Kim, S. [1 ]
Kim, H. [1 ]
Baek, E. J. [1 ]
Jin, H. [2 ]
Kim, J. [1 ]
Kim, H. O. [1 ]
机构
[1] Yonsei Univ, Coll Med, Dept Lab Med, Seoul, South Korea
[2] Yonsei Univ, Coll Med, Brain Korea Project Med Sci 21, Seoul, South Korea
关键词
CD34(+) cells; cryopreservation; engraftment; peripheral blood stem cell transplantation; viability;
D O I
10.1111/j.1423-0410.2007.01009.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives In peripheral blood stem cell transplantation, the number of CD34(+) cells infused is considered a predictor of haematopoietic engraftment. However, the currently accepted minimal threshold of CD34(+) cells/kg was determined by counting CD34(+) cells before freezing, and the loss of viable CD34(+) cells during freezing, cryopreservation or thawing prior to reinfusion has not been assessed. Materials and Methods Total and viable CD34(+) cells were quantified using single platform flow cytometry and viability dye, 7-amino actinomycin D (7-ADD), at the time of collection and prior to reinfusion in 46 peripheral haematopoietic stem cell grafts from 36 patients. The time to engraftment of neutrophil and platelet was assessed by routine peripheral blood cell counts performed daily. Results The median number of viable CD34(+) cells harvested was 3.6 x 10(6)/kg (range 0.05-21.2), and the median viability was 98% (range 70-100%) before freezing. After thawing, the median number of viable CD34(+) cells was reduced to 2.2 x 10(6)/kg (range 0.04-14.8) and the median viability was reduced to 71% (range 31-89%). The number of viable CD34(+) cells/kg before freezing and after thawing significantly correlated with engraftment of neutrophils (P < 0.0001 both) and platelets (P = 0.007 and 0.006, respectively). Although the minimum dose for engraftment (2.0 x 10(6) CD34(+) cells/kg) was harvested in 37 of 46 cases (85%), only 25 cases (54%) met this threshold at the time of reinfusion. For platelet engraftment, determination of viable CD34(+) cells prior to reinfusion was more important than enumeration at the time of collection. Conclusion Quantification of post-thaw viable CD34(+) cells better represents the actual composition of the graft and may be a more accurate predictor of haematopoietic engraftment than post-thaw total CD34(+) cell counts, or prefreeze determinations, especially for platelet engraftment. It is necessary to develop good quality controls for freezing and thawing procedures to minimize variance in cell viability.
引用
收藏
页码:146 / 152
页数:7
相关论文
共 50 条
  • [21] Impact of CD34+ Stem Cell Dose on Engraftment Period in Allogeneic Peripheral Blood Stem Cell Transplanted Patients
    Suria, A. A.
    Diyana, Hazlina B.
    Zakari, Zed A. H.
    Nurasyikin, Y.
    Yousuf, R.
    Azma, R. Z.
    MEDICINE AND HEALTH, 2021, 16 (01): : 39 - 49
  • [22] CD34+selected autologous peripheral blood stem cell transplantation (CD34+/ASCT) for multiple sclerosis
    Carreras, E
    Saiz, A
    Marín, P
    Martínez, C
    Rovira, M
    Villamor, N
    Aymerich, M
    Lozano, M
    Fernández-Avilés, F
    Urbano-Ispizua, A
    Berenguer, J
    Arbizu, T
    Montserrat, E
    Graus, F
    BONE MARROW TRANSPLANTATION, 2003, 31 : S16 - S16
  • [23] Autologous CD34+selected peripheral blood stem cell transplantation (CD34+/PBSCT) for multiple sclerosis
    Carreras, E
    Saiz, A
    Graus, F
    Marín, P
    Martínez, C
    Rovira, M
    Urbano-Ispizua, A
    Arbizu, T
    Casanova, B
    Mercader, JM
    Mazzara, R
    Merino, A
    Tolosa, E
    Montserrat, E
    BLOOD, 1999, 94 (10) : 398B - 398B
  • [24] The impact of CD34+ cell dose and comorbidities on engraftment following autologous hematopoietic stem cell transplantation (ASCT).
    Fiala, Mark A.
    Bhamidipati, Pavan Kumar
    Wang, Stephanie
    Sturgill, Trisha
    Gao, Feng
    Abboud, Camille N.
    Cashen, Amanda F.
    Jacoby, Meagan A.
    Pusic, Iskra
    Romee, Rizwan
    Schroeder, Mark A.
    Uy, Geoffrey L.
    Vij, Ravi
    Westervelt, Peter
    DiPersio, John F.
    Stockeri-Goldstein, Keith
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [25] Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease
    Cassinotti, A.
    Annaloro, C.
    Ardizzone, S.
    Onida, F.
    Della Volpe, A.
    Clerici, M.
    Usardi, P.
    Greco, S.
    Maconi, G.
    Porro, G. Bianchi
    Deliliers, G. Lambertenghi
    GUT, 2008, 57 (02) : 211 - 217
  • [26] CD34+ cell dose predicts costs after autologous peripheral blood stem cell transplantation for breast cancer
    Baron, F
    Copizza, S
    Baudoux, E
    Jerusalem, G
    Fillet, G
    Beguin, Y
    HAEMATOLOGICA, 2004, 89 (09) : 1146 - 1148
  • [27] Molecular remission in adult T cell leukemia after autologous CD34+ peripheral blood stem cell transplantation
    M Nakane
    K Ohashi
    Y Sato
    A Moriya
    T Inoue
    S Mori
    S Tanikawa
    H Akiyama
    Y Maeda
    T Sasaki
    K Karasawa
    Y Okuyama
    K Hiruma
    H Sakamaki
    Bone Marrow Transplantation, 1999, 24 : 219 - 221
  • [28] Molecular remission in adult T cell leukemia after autologous CD34+ peripheral blood stem cell transplantation
    Nakane, M
    Ohashi, K
    Sato, Y
    Moriya, A
    Inoue, T
    Mori, S
    Tanikawa, S
    Akiyama, H
    Maeda, Y
    Sasaki, T
    Karasawa, K
    Okuyama, Y
    Hiruma, K
    Sakamaki, H
    BONE MARROW TRANSPLANTATION, 1999, 24 (02) : 219 - 221
  • [29] Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation
    JE Kiss
    WB Rybka
    A Winkelstein
    M deMagalhaes-Silverman
    J Lister
    P D’Andrea
    ED Ball
    Bone Marrow Transplantation, 1997, 19 : 303 - 310
  • [30] Peripheral blood (PB) CD34+ count predict the success of progenitor cell collections for autologous stem cell transplant.
    Osma, MM
    Ortuño, F
    Moraleda, JM
    Sanchez, I
    Fernández, K
    Malo, MDG
    Ceballos, E
    Vicente, V
    BONE MARROW TRANSPLANTATION, 1999, 23 : S217 - S217